Zydus Cadila would be making a presentation on Lipagyln at the American Association of Clinical Endocrinologists (AACE) 24 th Annual Scientific and Clinical Congress to be held from 13 th to 17th of May 2015 at Nashville, Tennesse, USA. Further, the abstract titled ‘9 month safety and efficacy of Saroglitazar in Diabetic Dyslipidemia has been accepted for late breaking presentation at the AACE meeting.
Lipagyln was launched in September 2013 in India for treating Hypertriglyceridemia and Diabetic Dyslipidemia in patients with Type 2 diabetes not controlled by statins. Since then more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians.
Zydus Cadila is an innovation, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines.
